Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy - Top-Institutions - MDSpire

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy

  • By

  • M. Korenkov

  • J. Liebaert

  • S. Yousefian

  • S. Schwartz

  • U. M. Demel

  • J. Braune

  • M. C. Odabasi

  • L. Herzberg

  • D. Böckle

  • N. C. Görür

  • V. v. Landenberg-Roberg

  • S. Bohl

  • E. Tregel

  • S. Hennig

  • C. Franke

  • S. Haas

  • U. Keller

  • J. Krönke

  • A. Busse

  • October 20, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematologic Oncology
    • Neuroimmunology
    • Cellular Therapy

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neuroimmunology
    • Hematology
    • Neurology

  • #3

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Hematology-Oncology
    • Neuroimmunology
    • Cellular Therapy

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neuroimmunology
    • Hematology
    • Cellular Therapy

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Hematology-Oncology
    • Neuroimmunology
    • Cellular Therapy

Original Source(s)

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy

  • by M. Korenkov, J. Liebaert, S. Yousefian, S. Schwartz, U. M. Demel, J. Braune, M. C. Odabasi, L. Herzberg, D. Böckle, N. C. Görür, V. v. Landenberg-Roberg, S. Bohl, E. Tregel, S. Hennig, C. Franke, S. Haas, U. Keller, J. Krönke, A. Busse

  • October 20, 2025

Related Content

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma